Clinical-stage biopharmaceutical company Palisade Bio Inc (Nasdaq:PALI) announced on Tuesday the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board.

The company said that Dr. Verstockt is an internationally recognised expert in inflammatory bowel disease (IBD) and a leader in precision medicine and advanced, non-invasive disease assessment. This appointment further enhances Palisade's clinical and translational expertise, as the company prepares to advance PALI-2108 into Phase 2 development in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD).

"As we transition into Phase 2 development, optimising patient selection, endpoint strategy, and disease monitoring will be central to demonstrating meaningful clinical benefit," said Mitch Jones, MD, PhD, president and chief medical officer of Palisade Bio. "Dr. Verstockt is a global leader in precision medicine and non-invasive assessment in IBD. His expertise in advanced imaging, biomarker integration, and multi-omics research will be highly valuable as we design studies intended to efficiently demonstrate durable efficacy and disease modification in both UC and FSCD."

Dr. Verstockt is an IBD staff physician and professor in the Department of Gastroenterology and Hepatology at University Hospitals Leuven and KU Leuven, Belgium. His clinical and translational research on precision medicine in IBD focuses on disease heterogeneity, biomarker development, and non-invasive disease monitoring techniques, including intestinal ultrasound and advanced radiologic modalities.

Palisade plans to submit an Investigational New Drug (IND) application for a Phase 2 study of PALI-2108 in UC in the first half of 2026, with parallel development planning underway in FSCD.